LOGIN  |  REGISTER
Recursion
Assertio

Lantheus to Present at Upcoming Investor Conferences

February 21, 2025 | Last Trade: US$53.54 1.15 2.20

BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management team will present at the following upcoming investor conferences.

  • B. Riley Securities Precision Oncology & Radiopharma Day in New York on February 28
  • TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 2:30 pm ET
  • Leerink Global Healthcare Conference 2025 in Miami on March 11 at 1:40 pm ET

A live webcast will be available for the TD Cowen 45th Annual Health Care Conference and Leerink Global Healthcare Conference presentations on the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentations.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.

Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Melissa Downs
Senior Director, External Communications
646-975-2533
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Viking Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page